Associated tags: Paragon, Inflammation, Disease, Therapy, Patient, Psoriasis, Freedom, Biotechnology, ARCA, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, RTW, Engineering, Pharmaceutical industry
Locations: WALTHAM, MA, US, BS, INDIA
WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that Lawrence Klein, PhD, Chief Executive Officer will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m.
Key Points:
- WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that Lawrence Klein, PhD, Chief Executive Officer will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m.
- ET.
- To access a live webcast of the presentation, please visit: https://wsw.com/webcast/jeff302/orka/1841232 .
- An archive of the webcast will be available for replay for 90 days following the presentation.
Physiology,
Analytic,
Doctor of Philosophy,
Niagara University,
Control,
NDA,
Panwar,
University,
Messenger,
Therapy,
SVP,
Psoriasis,
Research,
Takeda Pharmaceutical Company,
CMC,
Moderna,
Magenta,
Head,
Retina,
Toxicology,
Pharmacy,
Dentistry,
Biotechnology,
Antibody,
Gene editing,
GMP WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the appointment of Joe Senn, PhD, as Senior Vice President of Nonclinical Research & Development. Dr. Senn is a research and development leader with experience in nearly all therapeutic modalities, including biologics, mRNA therapeutics, gene editing, and small molecules. He has built broad expertise in pharmacology and toxicology through leading the advancement of over 50 programs from preclinical stage into clinical development, including multiple monoclonal antibody programs.
Key Points:
- Dr. Senn is a research and development leader with experience in nearly all therapeutic modalities, including biologics, mRNA therapeutics, gene editing, and small molecules.
- In addition, Oruka announced the appointment of Rajiv Panwar, PhD, as Vice President and Head of Chemistry, Manufacturing, and Controls (CMC).
- Dr. Panwar brings deep experience in biologics manufacturing, having previously served in CMC leadership roles at Disc Medicine and Magenta Therapeutics.
- “We are excited to strengthen our growing executive team with the addition of these two industry leaders.
Retrieved on:
Wednesday, April 24, 2024
University,
CMO,
Safety,
NDA,
Skin,
Leo Pharma,
Dermatology,
Doctor of Philosophy,
Freedom,
Engineering,
Patient,
Doctor of Pharmacy,
Secukinumab,
Psoriasis,
Therapy,
Celgene,
Biotechnology,
Chronic kidney disease,
Pharmaceutical industry WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the strengthening of its leadership team with the addition of two experienced executives.
Key Points:
- Joana Goncalves, MBChB, will serve as Oruka’s Chief Medical Officer, effective April 18, 2024.
- Dr. Goncalves brings two decades of leadership experience in dermatology clinical development and medical affairs.
- Oruka also announced that Eugenia Levi, PharmD, will join the company as Vice President of Medical Affairs.
- Her extensive leadership experience will prove invaluable as we advance our portfolio of potentially best-in-class antibodies and build a high-performing team,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics.
Paragon,
Freedom,
Psoriasis,
Biotechnology,
ARCA,
Disease,
Patient,
Paradigm,
Psoriatic arthritis,
Standard of care,
Doctor of Philosophy,
Investment,
RTW,
Engineering,
Pharmaceutical industry WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
Key Points:
- Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
- In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
- “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
- Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).
Paragon,
Freedom,
Psoriasis,
Biotechnology,
ARCA,
Disease,
Patient,
Paradigm,
Psoriatic arthritis,
Standard of care,
Doctor of Philosophy,
Investment,
RTW,
Engineering,
Pharmaceutical industry WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
Key Points:
- Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
- In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
- “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
- Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).
